BPC-157 and TB-500 are marketed almost interchangeably in many recovery-focused peptide protocols, sometimes even combined in a single product. It's worth understanding how they actually differ, and where their evidence genuinely stands, individually.
Different Origins, Similar Marketing
BPC-157, detailed in this site's dedicated guide, is derived from a gastric protective protein and was originally studied for gut-related protection before its research expanded into broader tissue repair. TB-500 is derived from thymosin beta-4, a protein involved in cell migration and wound healing more generally. Despite these distinct biological origins, both are marketed today primarily around the same general claim: faster recovery from tendon, ligament, and soft tissue injury.
Comparing the Evidence Base
Both compounds share a similar overall evidence profile, animal and cell-culture research suggesting plausible mechanisms, with no completed, published human clinical trials establishing efficacy or dosing for either compound specifically. Neither has meaningfully more human evidence than the other at this point, despite each having a slightly different research history and mechanism.
Regulatory Status Is Identical
Both were separately evaluated and both were excluded from the FDA's list of substances eligible for pharmacy compounding, discussed in this site's news coverage of that determination, putting them in the same regulatory position: not FDA-approved, not compounding-eligible, available only through the unregulated research-chemical market.
Why They're Often Combined
Some protocols combine both compounds on the theory that their somewhat different proposed mechanisms, BPC-157's broader tissue-protective effects and TB-500's cell-migration and wound-healing effects, might work complementarily. This combination theory hasn't itself been tested in any controlled study, human or animal, so it represents an additional layer of unproven assumption stacked on top of each individual compound's own limited evidence.
The Bottom Line
Despite different biological origins, BPC-157 and TB-500 currently sit in essentially the same evidentiary position: promising preclinical research, no human trials, and identical regulatory exclusion from legitimate compounding. Neither has a meaningfully stronger evidence-based claim to effectiveness than the other at this point.
Why "Which Is Better" Isn't Really Answerable Yet
Because neither compound has completed human trials, there's no reliable evidence-based way to declare one more effective than the other for any specific injury type, despite how often this exact comparison comes up in forum discussions and vendor marketing. Any claimed advantage of one over the other circulating online is, at this point, necessarily based on anecdote or animal-study extrapolation rather than a head-to-head human comparison that simply doesn't exist yet.